Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integral Diagnostics Ltd. ( (AU:IDX) ) has provided an update.
Integral Diagnostics has disclosed a change in the shareholding of non-executive director Laura McBain, who increased her indirect interest in the company through an on-market purchase. Via Vermilion 21 Pty Ltd as trustee for the McNelhaus Super Fund, McBain acquired 8,474 fully paid ordinary shares at $2.35 each on 6 March 2026, lifting her holding from 14,776 to 23,250 shares.
The transaction, recorded as an on-market trade and notified under ASX listing rule 3.19A.2, signals a higher personal financial exposure by McBain to Integral Diagnostics’ equity. While the filing is primarily compliance-driven, the additional share purchase may be interpreted by some investors as a sign of director confidence in the company’s prospects, albeit based solely on this disclosed transaction.
The most recent analyst rating on (AU:IDX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Limited is an Australian healthcare company operating in the diagnostic imaging sector. It provides radiology and related imaging services, with its shares listed and traded on the ASX, giving investors exposure to medical diagnostics demand across Australia.
Average Trading Volume: 698,077
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$879.6M
See more insights into IDX stock on TipRanks’ Stock Analysis page.